Search filters

List of works by David M Hyman

A Next-Generation TRK Kinase Inhibitor Overcomes Acquired Resistance to Prior TRK Kinase Inhibition in Patients with TRK Fusion-Positive Solid Tumors

scientific article published on 3 June 2017

AKT mutant allele-specific activation dictates pharmacologic sensitivities

scientific article published on 19 April 2022

Activating mutations in CSF1R and additional receptor tyrosine kinases in histiocytic neoplasms

scientific article published on 25 November 2019

Characterization of a novel germline PALB2 duplication in a hereditary breast and ovarian cancer family

scientific article published on 18 October 2016

Clinical tumour sequencing for precision oncology: time for a universal strategy

scientific article published on 01 September 2018

Designing and evaluating health systems level hypertension control interventions for African-Americans: lessons from a pooled analysis of three cluster randomized trials

scientific article

Detection of HER2-Positive Metastases in Patients with HER2-Negative Primary Breast Cancer Using 89Zr-Trastuzumab PET/CT

scientific article published on 05 May 2016

Efficacy of Larotrectinib in TRK Fusion-Positive Cancers in Adults and Children.

scientific article published in February 2018

Gemcitabine for advanced endometrial cancer: a retrospective study of the Memorial sloan-Kettering Cancer Center experience

scientific article

Genome doubling shapes the evolution and prognosis of advanced cancers

scientific article published on 16 July 2018

High-intensity sequencing reveals the sources of plasma circulating cell-free DNA variants

scientific article published on 25 November 2019

Identification of HER2-Positive Metastases in Patients with HER2-Negative Primary Breast Cancer by Using HER2-targeted 89Zr-Pertuzumab PET/CT

scientific article published on 09 June 2020

NTRK fusion detection across multiple assays and 33,997 cases: diagnostic implications and pitfalls

scientific article published on 02 August 2019

Neratinib is effective in breast tumors bearing both amplification and mutation of ERBB2 (HER2)

scientific article published on 09 October 2018

Oncogenic TRK fusions are amenable to inhibition in hematologic malignancies

scientific article published on 06 August 2018

Parallel phase Ib studies of two schedules of buparlisib (BKM120) plus carboplatin and paclitaxel (q21 days or q28 days) for patients with advanced solid tumors.

scientific article

Patient HLA class I genotype influences cancer response to checkpoint blockade immunotherapy

scientific article

Phase 2 study of LY3023414 in patients with advanced endometrial cancer harboring activating mutations in the PI3K pathway

scientific article published on 27 December 2019

Precision oncology: Charting a path forward to broader deployment of genomic profiling

scientific article

RAF inhibitor PLX8394 selectively disrupts BRAF dimers and RAS-independent BRAF-mutant-driven signaling

scientific article published on 17 December 2018

Research Needs to Improve Hypertension Treatment and Control in African Americans

scientific article published on 12 September 2016

Resistance to TRK inhibition mediated by convergent MAPK pathway activation

scientific article published on 12 August 2019

The evolution of RET inhibitor resistance in RET-driven lung and thyroid cancers

scientific article published on 18 March 2022

Understanding inherited risk in unselected newly diagnosed patients with endometrial cancer

scientific article published on 25 April 2019

Paulina is supported by:

About Paulina

Help